Jonathan N Barker
Overview
Explore the profile of Jonathan N Barker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
3508
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dand N, Stuart P, Bowes J, Ellinghaus D, Nititham J, Saklatvala J, et al.
Nat Commun
. 2025 Feb;
16(1):2051.
PMID: 40021644
Psoriasis is a common, debilitating immune-mediated skin disease. Genetic studies have identified biological mechanisms of psoriasis risk, including those targeted by effective therapies. However, the genetic liability to psoriasis is...
2.
Kroah-Hartman M, Lee J, Dooley N, Tan W, Mineur M, Paolino A, et al.
Br J Dermatol
. 2025 Feb;
PMID: 39999378
No abstract available.
3.
Schwarz C, Blegvad C, Baudry D, Tosi I, Lee S, Chung R, et al.
J Invest Dermatol
. 2025 Feb;
PMID: 39983980
No abstract available.
4.
Gordon K, Tada Y, Anadkat M, Choon S, Elewski B, Barker J, et al.
Dermatol Ther (Heidelb)
. 2025 Feb;
15(2):395-411.
PMID: 39928095
Introduction: Spesolimab, a selective, humanised monoclonal antibody targeting the interleukin-36 receptor, is approved for the treatment of generalised pustular psoriasis (GPP). As a result of the limited patient numbers in...
5.
Barker J, Casanova E, Choon S, Foley P, Fujita H, Gonzalez C, et al.
Br J Dermatol
. 2025 Jan;
PMID: 39844356
Background: Generalised pustular psoriasis (GPP) is a chronic, systemic, neutrophilic inflammatory disease. A previous Delphi panel established areas of consensus on GPP, although patient perspectives were not included, and aspects...
6.
GWAS Meta-Analysis Identifies Susceptibility Loci for Keloids and Hypertrophic Scarring in Europeans
Dand N, Ung C, Saklatvala J, Simpson M, Barker J, Shaw T, et al.
J Invest Dermatol
. 2025 Jan;
PMID: 39746571
No abstract available.
7.
Ramessur R, Saklatvala J, Budu-Aggrey A, Ostaszewski M, Mobus L, Greco D, et al.
JAMA Cardiol
. 2024 Sep;
9(11):1009-1017.
PMID: 39292496
Importance: The epidemiological link between immune-mediated diseases (IMIDs) and cardiovascular disease has often been attributed to systemic inflammation. However, the direction of causality and the biological mechanisms linking cardiovascular disease...
8.
Farag A, Visvanathan S, Bachelez H, Morita A, Lebwohl M, Barker J, et al.
J Invest Dermatol
. 2024 Jul;
145(3):573-582.e8.
PMID: 39004117
EFFISAYIL 1 was a randomized, placebo-controlled study of spesolimab, an anti-IL-36 receptor antibody, in patients presenting with a generalized pustular psoriasis flare. Treatment with spesolimab led to more rapid pustular...
9.
Barker J, Becher G, Burden D, Pink A, Zacharioudaki M, Warren R
Skin Health Dis
. 2024 Jun;
4(3):e359.
PMID: 38846692
This article presents the results of the UK extension of a previously conducted global Delphi panel on generalised pustular psoriasis (GPP). Five UK based dermatologists experienced in GPP management have...
10.
Hernandez-Cordero A, Thomas L, Smail A, Lim Z, Saklatvala J, Chung R, et al.
J Allergy Clin Immunol
. 2024 May;
154(3):657-665.e9.
PMID: 38815935
Background: Palmoplantar pustulosis (PPP) is an inflammatory skin disorder that mostly affects smokers and manifests with painful pustular eruptions on the palms and soles. Although the disease can present with...